Cargando…
HGG-14. TREATMENT AND PROGNOSTIC FACTORS FOR PEDIATRIC GLIOBLASTOMAS--THE 10 YEARS EXPERIENCE FROM ONE SINGLE CENTER
OBJECTIVE: We retrospectively analyzed the clinical features of pediatric glioblastoma patients in our center in the past 10 years. METHODS: From November 2009 to December 2018, patients with glioblastoma under 18 years were admitted to Guangdong Sanjiu Brain Hospital. Clinical and pathological feat...
Autores principales: | Li, Juan, Lai, Mingyao, Hu, Qingjun, Zhou, Cheng, Zhou, Zhaoming, Shan, Changguo, Hong, Weiping, Zhang, Xing, Zhang, Yangqiong, Luo, Rishun, Wang, Lichao, Lu, Ming, Cai, Linbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715068/ http://dx.doi.org/10.1093/neuonc/noaa222.302 |
Ejemplares similares
-
HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022) -
HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020) -
HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN
por: Pietsch, Torsten, et al.
Publicado: (2020) -
HGG-41. CHARACTERIZATION OF THE IMMUNE RESPONSE FOLLOWING VARIOUS RADIOTHERAPY TREATMENTS IN GLIOBLASTOMA
por: Cocito, Carolina, et al.
Publicado: (2021) -
HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma
por: Guerrini-Rousseau, Lea, et al.
Publicado: (2022)